Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,129 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Neck Neoplasms Clear all

Conditions: Basal Cell Carcinoma of the Head and Neck
Interventions: Pembrolizumab, Tissue collection; Drug · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions: doxepin hydrochloride, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 120
States / cities: Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more

Conditions: Breast Cancer
Interventions: Transcutaneous vagus nerve and acupuncture point stimulation; Device
Lead sponsor: The Healing Consciousness Foundation; Other
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Meadowbrook, Pennsylvania

Conditions: Squamous Cell Carcinoma of the Oral Cavity
Interventions: Antitumor B; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Esophageal Cancer, Stomach Cancer, Pancreatic Cancer
Interventions: Specimen collection; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
Interventions: CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]; Drug
Lead sponsor: Cytovation AS; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: MEDI4736, tremelimumab; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 21
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 16 more

Conditions: Solid Tumors
Interventions: Bemarituzumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Duarte, California • Orange, California • Aurora, Colorado + 7 more

Conditions: Head and Neck Cancer, Breast Cancer, Head and Neck Cancers, Non-Hodgkin Lymphoma, Colorectal Adenocarcinoma
Interventions: FNA Biopsy; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 21 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Stanford, California

Conditions: Squamous Cell Carcinoma of Head and Neck, Squamous Cell Carcinoma of Head and Neck (SCCHN), HNSCC, Neoplasm Recurrence, Local, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: TMV Vaccine, Toripalimab-tpzi; Biological
Lead sponsor: Metaclipse Therapeutics Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Head and Neck Squamous Cell Carcinoma
Interventions: CDX-3379 and cetuximab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 10
States / cities: Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 7 more

Conditions: Cervical Cancer, Sexuality and Reproductive Issues
Interventions: management of therapy complications; Procedure
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Up to 69 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 12
States / cities: Savannah, Georgia • Kalamazoo, Michigan • Kalamazooaa, Michigan + 8 more

Conditions: Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma
Interventions: Cetuximab; Biological
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 22
States / cities: Aurora, Colorado • New Britain, Connecticut • Decatur, Illinois + 18 more

Conditions: Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
Interventions: Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy; Drug · Radiation
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Gilbert, Arizona • Tucson, Arizona • Seattle, Washington

Conditions: Head and Neck Cancer
Interventions: e-learning didactic module, Personal reflection activities; Behavioral
Lead sponsor: Bethany Rhoten; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Cancer
Interventions: PET/CT Imaging; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma
Interventions: Itraconazole; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 7
States / cities: Palo Alto, California • Ann Arbor, Michigan • Durham, North Carolina + 4 more

Conditions: Head and Neck Cancer
Interventions: Cetuximab, Nab-paclitaxel, Carboplatin; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Nashville, Tennessee • Seattle, Washington

Conditions: Head and Neck Cancer
Interventions: DNA Vaccine, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer, Dental Diseases, Osteoradionecrosis
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 6
States / cities: Farmington, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Head and Neck Neoplasms, Fibrosis, Lymphedema, Biomarkers, Polymorphism, Genetic, Depression
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Carcinoma
Interventions: Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HER-2 Gene Amplification, Esophagus Cancer, Gastroesophageal Junction Cancer, Stomach Cancer
Interventions: MM-111, Paclitaxel, Trastuzumab; Drug
Lead sponsor: Merrimack Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: Pembrolizumab, Nivolumab; Drug
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dublin, Ohio

Search by objective public record fields.

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

MindVybe tVNS/APS for Wellbeing in Breast Cancer Survivors

Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer

Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

FNA Tumor Sampling for CD137 Modulation: A Pilot Study

TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Vaginal Changes and Sexual Function in Patients With Cervical Cancer

Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Body Image After Head and Neck Cancer Treatment

Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in HNC Patients Using PET/CT

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

Clinical Registry of Long-Term Dental Outcomes in Head and Neck Cancer Patients

The Fibrosis-Lymphedema Continuum in Head and Neck Cancer

Clinical Data Collection in Studying Clinical Factors Associated With Post-Surgery Chronic Opioid Use in Patients With Head and Neck Cancers

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma